Start up at a low cost

Houston named among the most affordable cities for startups

Houston has affordablility going for its startups. Photo by Zview/Getty Images

Houston has been long known for its great quality of life and low cost of living, and a new study found that when it comes to startup companies specifically, the greater Houston area has a lot to offer.

Clever, a real estate tool and blog, identified Houston as the sixth best metro in the United States for affordability for startups. The study looked into startup density, investment, the education level of the local population, and the cost of living, and more within the top 50 most populated cities in the U.S.

The resulting ranking had all four of Texas' major metros in the top 10. Austin ranked No. 1 overall, Dallas-Fort Worth ranked at No. 3 (after Atlanta), and San Antonio-New Braunfels came in at No. 8. The study ranked each city based on its density of startups, its growth, investment in business, and its cost of living.

At No. 6 for growth, Houston ranked the highest out of its Texas counterparts, but San Antonio and Houston share the ranking of No. 6 for investment.

"Considering Houston's metro is tied with San Antonio's for the highest average investment in small business, and the proximity to great food, the Gulf of Mexico coast, and attractions like Minute Maid Park and the NASA Space Center, we would definitely suggest considering starting a business here," reads the report.

The Houston area touts a startup density of over 25 percent, which earns it 12th place in that particular category. The report finds that Houston has 6.89 million residents across 8,265.8 square miles and 6.54 percent of Houstonians work at a startup, while 2.8 percent are self employed.

When it comes to GDP and education, Houston has a lot of bragging rights. The Houston area's GDP is reported to be $490 billion, which is the 7th highest in the country, according to the Bureau of Economic Analysis.Meanwhile, almost a quarter of the region's population has a bachelor's degree or higher.

Last month, InnovationMap reported that Inc. 5000 named Houston among its hottest startup cities, citing the three-year revenue growth of Houston's companies that made it on to the Inc. 5000 list. Just before that ranking, Business Facilities magazine named Houston the fourth best startup ecosystem in the U.S., as well as the fourth best city for economic growth potential. Similarly, Commercial Cafe recently named Houston a top large city for early stage startups.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News